A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
← catalyst calendarNCT07639021 · readout in 326 d
Sponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
230estimated
Sites
25
Countries
Puerto Rico, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-06-09 | actual | When the study began enrolling |
| Primary completion | 2027-07-12 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-07-12 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Obesity
Interventions
- Drug: NNC0662-0419
- Drug: Semaglutide
- Drug: NNC0662-0419 Placebo
- Drug: Semaglutide placebo
Primary outcome
what the primary-completion date above is the date OFNumber of gastrointestinal adverse events
measured From week 0 to week 39
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed